Category Archives: Engagement and Care Cascade

Drug resistance mutations in HIV: New bioinformatics approaches and challenges

2021

Drug resistance mutations appear in HIV under treatment pressure. Resistant variants can be transmitted to treatment-naive individuals, which can lead to rapid virological failure and can limit treatment options. Consequently,...

HIV-proteins-associated CNS neurotoxicity, their mediators, and alternative treatments

2021

Human immunodeficiency virus (HIV)-infected people’s livelihoods are gradually being prolonged with the use of combined antiretroviral therapy (ART). Conversely, despite viral suppression by ART, the symptoms of HIV-associated neurocognitive disorder...

TLR-agonist mediated enhancement of antibody-dependent effector functions as strategy for an HIV-1 cure

2021

BACKGROUND: The current treatment for HIV-1 is based on blocking various stages in the viral replication cycle using combination antiretroviral therapy (ART). Even though ART effectively controls the infection, it...

The influence of HLA/HIV genetics on the occurrence of elite controllers and a need for therapeutics geotargeting view

2021

The interaction of HIV-1, human leukocyte antigen (HLA), and elite controllers (EC) compose a still intricate triad. Elite controllers maintain a very low viral load and a normal CD4 count,...

Health programmes and services addressing the prevention and management of infectious diseases in people who inject drugs in Canada: A systematic integrative review

2021

OBJECTIVES: People who inject drugs (PWID) experience a high burden of injection drug use-related infectious disease and challenges in accessing adequate care. This study sought to identify programmes and services...

Cardiometabolic complications in youth with perinatally acquired HIV in the era of antiretroviral therapy

2021

PURPOSE OF REVIEW: Antiretroviral therapy (ART) scale-up has dramatically reduced rates of pediatric HIV mortality and morbidity. Children living with perinatally acquired HIV (PHIV) are now expected to live through...

HIV care outcomes among transgender persons with HIV infection in the united states: A systematic review and meta-analysis, 2006–2021

2021

Objectives: HIV prevalence is an estimated 14% among transgender women (TW) and 3% among transgender men (TM). HIV care is vital for viral suppression but is hindered by transphobia and HIV...

HIV care continuum interventions for Black men who have sex with men in the USA

2021

Disparities persist along the HIV care continuum among Black men who have sex with men (MSM) in the USA. As part of an initiative funded by the Health Resources and...

Pharmacy-based interventions to increase use of HIV pre-exposure prophylaxis in the United States: A scoping review

2021

HIV pre-exposure prophylaxis (PrEP) remains underutilized in the U.S. Since greater than 85% of PrEP prescriptions are filled at commercial pharmacies, pharmacists are uniquely positioned to increase PrEP use. This...

NK cell-based therapies for HIV infection: Investigating current advances and future possibilities

2021

NK cells are well-known for their antiviral functions. Also, their role in HIV has been well established, with rapid responses elicited during early HIV infection. Most immune cells including CD4(+)...

Testing for saturation in qualitative evidence syntheses: An update of HIV adherence in Africa

2021

BACKGROUND: A systematic review of randomised trials may be conclusive signalling no further research is needed; or identify gaps requiring further research that may then be included in review updates....

Non-vertical exposures to HIV, HBV and HCV infection in children and adolescents-risk of infection, standards of care and postexposure prophylaxis

2021

INTRODUCTION: in the review, we aimed to present current knowledge about the risk of infection, standards of care, and postexposure prophylaxis (PEP) in pediatric patients after non-vertical exposures to HIV,...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!